Barclays
APLS

Barclays’s Apellis Pharmaceuticals APLS Stock Holding History

Barclays’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,400
Closed -$35.2K – 5026
2025
Q4 		$35.2K Buy
+1,400
New +$32.8K ﹤0.01% 4791
2023
Q4 		– Sell
-256,400
Closed -$9.75M – 5217
2023
Q3 		$9.75M Buy
+256,400
New +$11.3M 0.01% 1006

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Barclays's APLS Position: Q1 2026 in Review

Barclays reduced its Apellis Pharmaceuticals (APLS) stake by 48% in Q1 2026, selling an estimated $1.93M and leaving 98,327 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Barclays first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. The position peaked at $35.5M in Q4 2019. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Barclays held 98,327 shares of Apellis Pharmaceuticals worth $3.96M as of Q1 2026.
  • Barclays sold 89,385 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.93M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1965 holding.
  • Barclays first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Barclays's Apellis Pharmaceuticals position peaked at $35.5M in Q4 2019.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.